Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ: CVAC )

3.025 +0.035 (+1.17%)
Streaming Delayed Price Updated: 12:48 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Why CureVac Shares Are Falling
CureVac BV (NASDAQ: CVAC) shares are trading lower after the company and Bayer reportedly terminated their vaccine manufacturing partnership. More news came around 1:20 pm... 
Via Benzinga
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions - Expansion part of Phase 1 study fully recruited;... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
Why CureVac Stock Is Tumbling Today
The company is throwing in the towel on its first-generation COVID-19 vaccine candidate. 
Via The Motley Fool
Exposures COVID-19
Why CureVac Shares Are Trading Lower Today
CureVac NV (NASDAQ: CVAC) is trading lower Tuesday after the company announced it will focus its COVID-19 vaccine development towards the development of second-gen mRNA... 
Via Benzinga
Exposures COVID-19
51 Biggest Movers From Friday
Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares jumped 38.1% to close at $4.75 on Friday after declining around 15% on Thursday. The company recently announced it... 
Via Benzinga
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK - First-generation vaccine candidate, CVnCoV, to be withdrawn from... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
54 Biggest Movers From Friday
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc.... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. 
Via InvestorPlace
Exposures COVID-19
Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting
The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel... 
Via Benzinga
Exposures COVID-19
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
Exposures COVID-19
Breaking Down The Inflation Numbers Draws Attention To Oil Prices
Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However,... 
Via Benzinga
Exposures Fossil Fuels
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. 
Via Talk Markets
Exposures COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would... 
Via Benzinga
Exposures COVID-19
Why CureVac's Stock Is Down During Today's Session
CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European... 
Via Benzinga
CureVac Streamlines European Network for mRNA Product Manufacturing
- CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands - Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis - Further research aimed at optimizing mRNA... 
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures COVID-19 Death Intellectual Property
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
It isn't likely. 
Via The Motley Fool
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
4 High-Yield Dividend Stocks to Boost Your Dividend Income
Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels. 
Via Talk Markets
Boehringer Ingelheim Scraps Lung Cancer Program With CureVac
CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today
Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.